Formycon AG - ESG Rating & Company Profile powered by AI
This Sustainability rating for Formycon AG represents its reporting of the UN SDGs. The assessment of Formycon AG was prepared by All Street Sevva using proprietary Cognitive Robots. This webpage is a zero-cost Environmental, Social and Governance report covering Formycon AG.
Formycon AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.0; made up of an environmental score of 4.8, social score of 4.8 and governance score of 5.3.
5.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 999 | Xeris Pharmaceuticals Inc | 5.1 | High |
| 999 | Vascular Biogenics Ltd | 5.1 | High |
| 1047 | Formycon AG | 5.0 | High |
| 1047 | Anixa Biosciences Inc | 5.0 | High |
| 1047 | Amarin Corporation PLC | 5.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Formycon AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Formycon AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Formycon AG report the average age of the workforce?
Sign up for free to unlockDoes Formycon AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Formycon AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Formycon AG disclose cybersecurity risks?
Sign up for free to unlockDoes Formycon AG offer flexible work?
Sign up for free to unlockDoes Formycon AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Formycon AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Formycon AG conduct supply chain audits?
Sign up for free to unlockDoes Formycon AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Formycon AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Formycon AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Formycon AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Formycon AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Formycon AG disclose water use targets?
Sign up for free to unlockDoes Formycon AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Formycon AG have a product recall in the last two years?
Sign up for free to unlockDoes Formycon AG disclose incidents of discrimination?
Sign up for free to unlockDoes Formycon AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Formycon AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Formycon AG disclose parental leave metrics?
Sign up for free to unlockDoes Formycon AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Formycon AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Formycon AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Formycon AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Formycon AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Formycon AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Formycon AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Formycon AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Formycon AG disclose its waste policy?
Sign up for free to unlockDoes Formycon AG report according to TCFD requirements?
Sign up for free to unlockDoes Formycon AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Formycon AG disclose energy use targets?
Sign up for free to unlockDoes Formycon AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Formycon AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Formycon AG
These potential risks are based on the size, segment and geographies of the company.
Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.